Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis
- 118 Downloads
- 18 Citations
Abstract
Osteoporosis is becoming a major public health problem in Asian countries, with a rapid increase in osteoporotic fractures projected as urbanization increases, particularly in China. The purpose of this post hoc analysis was to assess the effects of 12 months of treatment with raloxifene on the incidence of clinical fractures in postmenopausal Asian women, compared to a placebo, by combining two independently designed studies (one Japanese study and one Chinese study). A total of 488 women, 284 in Japan and 204 in China were included in the analysis. Baseline characteristics (mean ± SD) for the Japanese and Chinese women were: age, 64.8 ± 6.3 years and 65.3 ± 6.0 years; body mass index, 21.8 ± 2.8 kg/m2 and 23.0 ± 2.9 kg/m2; and prevalent vertebral fractures, 26.4% and 13.7%, respectively. In both studies, the clinical vertebral and nonvertebral fractures were confirmed by radiographs or clinical reports at a central research facility. From the two combined studies, the incidence of new clinical vertebral fractures was significantly lower in the raloxifene 60 mg/day (RLX60) group (0 out of 194, P = 0.01) and in the pooled raloxifene group (those taking 60 mg/day and those taking 120 mg/day) (0 out of 289, P = 0.002), compared with the placebo group (7 out of 199, 3.5%). The pooled raloxifene group, as well as the RLX60 group, also had a significantly lower incidence of any new clinical fracture (P = 0.001 and P = 0.01, respectively) compared to the placebo group. In conclusion, raloxifene treatment at 60 mg/day for 1 year resulted in a significant reduction in the risk of new clinical vertebral fractures and any new clinical fracture in postmenopausal Asian women with osteoporosis.
Key words
raloxifene clinical fractures vertebral fractures nonvertebral fractures Japanese ChinesePreview
Unable to display preview. Download preview PDF.
References
- 1.Orimo, H Hashimoto, T Sakata, K Yoshimura, N Suzuki, T Hosoi, T General Research Committee for Prevention of Osteoporosis, Ministry of Health and Welfare, Tokyo Metropolitan Geriatric Hospital, Japan2000Trends in the incidence of hip fracture in Japan, 1987–1997: the third nationwide surveyJ Bone Miner Metab18126131PubMedCrossRefGoogle Scholar
- 2.Lufkin, EG, Wong, M, Deal, C 2001The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosisRheum Dis Clin North Am27163185PubMedCrossRefGoogle Scholar
- 3.Maricic, M, Adachi, JD, Sarkar, S, Wu, W, Wong, M, Harper, KD 2002Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosisArch Intern Med16211401143PubMedCrossRefGoogle Scholar
- 4.Qu, Y, Wong, M, Thiebaud, D, Stock, JL 2005The effect of raloxifene therapy on the risk of new clinical vertebral fractures at 3 and 6 months: a secondary analysis of the MORE trialCurr Med Res Opin2119551959PubMedCrossRefGoogle Scholar
- 5.Morii, H, Ohashi, Y, Taketani, Y, Fukunaga, M, Nakamura, T, Itabashii, A, Sarkar, S, Harper, K 2003Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trialOsteoporos Int4793800CrossRefGoogle Scholar
- 6.Liu, J, Zhu, H, Huang, Q, Zhang, Z, Li, H, Qin, Y, Zhang, Y, Wei, D, Lu, J, Liu, H, Chen, X, Liu, Y, Ekangaki, A, Southby, J, Diez-Perez, A 2004Effects of raloxifene (RLX) on bone mineral density (BMD), and serum lipids in Chinese postmenopausal women with osteoporosisChin Med J11710291035PubMedGoogle Scholar
- 7.Genant, HK, Jergas, M, Palermo, L, Nevitt, M, Valentin, RS, Black, D, Cummings, SR 1996Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosisJ Bone Miner Res11984996PubMedCrossRefGoogle Scholar
- 8.Delmas, PD Ensrud, KE Adachi, JD Harper, KD Sarker, S Gennari, C Reginster, JY Pols, HAP Recker, RR Harris, ST Wu, W Genant, HK Black, DM Eastell, R for the Multiple outcomes of raloxifene evaluation (MORE) investigators2002Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trialJ Clin Endocrinol Metab8736093617PubMedCrossRefGoogle Scholar
- 9.Ettinger, B Black, DM Mitlak, BH Knickerbocker, RK Nickelsen, T Genat, HK Christiansen, C Delmas, PD Zanchetta, JR Stakkestad, J Glüer, CC Krueger, K Cohen, FJ Eckert, S Ensrud, KE Avioli, LV Lips, P Cummings, SR for the Multiple outcomes of raloxifene evaluation (MORE) investigators1999Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trialJAMA282637645PubMedCrossRefGoogle Scholar
- 10.Delmas, PD, Genant, HK, Crans, GG, Stock, JL, Wong, M, Siris, E, Adachi, JD 2003Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trialBone33522532PubMedCrossRefGoogle Scholar